• Je něco špatně v tomto záznamu ?

Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1)

J. Hofman, R. Kučera, D. Cihalova, J. Klimes, M. Ceckova, F. Staud,

. 2013 ; 8 (10) : e75520.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14063905

Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various cancers; nevertheless, data regarding interaction of these substances with drug efflux transporters is still lacking. Recently, we have demonstrated inhibition of breast cancer resistance protein (ABCG2) by olomoucine II and purvalanol A and shown that these compounds are able to synergistically potentiate the antiproliferative effect of mitoxantrone, an ABCG2 substrate. In this follow up study, we investigated whether olomoucine II and purvalanol A are transported by ABCG2 and ABCB1 (P-glycoprotein). Using monolayers of MDCKII cells stably expressing human ABCB1 or ABCG2, we demonstrated that olomoucine II, but not purvalanol A, is a dual substrate of both ABCG2 and ABCB1. We, therefore, assume that pharmacokinetics of olomoucine II will be affected by both ABCB1 and ABCG2 transport proteins, which might potentially result in limited accumulation of the compound in tumor tissues or lead to drug-drug interactions. Pharmacokinetic behavior of purvalanol A, on the other hand, does not seem to be affected by either ABCG2 or ABCB1, theoretically favoring this drug in the potential treatment of efflux transporter-based multidrug resistant tumors. In addition, we observed intensive sulfatation of olomoucine II in MDCKII cell lines with subsequent active efflux of the metabolite out of the cells. Therefore, care should be taken when performing pharmacokinetic studies in MDCKII cells, especially if radiolabeled substrates are used; the generated sulfated conjugate may largely contaminate pharmacokinetic analysis and result in misleading interpretation. With regard to chemical structures of olomoucine II and purvalanol A, our data emphasize that even drugs with remarkable structure similarity may show different pharmacokinetic behavior such as interactions with ABC transporters or biotransformation enzymes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14063905
003      
CZ-PrNML
005      
20140707113453.0
007      
ta
008      
140704s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0075520 $2 doi
035    __
$a (PubMed)24116053
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hofman, Jakub $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy, Hradec Kralove, Czech Republic.
245    10
$a Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) / $c J. Hofman, R. Kučera, D. Cihalova, J. Klimes, M. Ceckova, F. Staud,
520    9_
$a Purine cyclin-dependent kinase inhibitors have been recognized as promising candidates for the treatment of various cancers; nevertheless, data regarding interaction of these substances with drug efflux transporters is still lacking. Recently, we have demonstrated inhibition of breast cancer resistance protein (ABCG2) by olomoucine II and purvalanol A and shown that these compounds are able to synergistically potentiate the antiproliferative effect of mitoxantrone, an ABCG2 substrate. In this follow up study, we investigated whether olomoucine II and purvalanol A are transported by ABCG2 and ABCB1 (P-glycoprotein). Using monolayers of MDCKII cells stably expressing human ABCB1 or ABCG2, we demonstrated that olomoucine II, but not purvalanol A, is a dual substrate of both ABCG2 and ABCB1. We, therefore, assume that pharmacokinetics of olomoucine II will be affected by both ABCB1 and ABCG2 transport proteins, which might potentially result in limited accumulation of the compound in tumor tissues or lead to drug-drug interactions. Pharmacokinetic behavior of purvalanol A, on the other hand, does not seem to be affected by either ABCG2 or ABCB1, theoretically favoring this drug in the potential treatment of efflux transporter-based multidrug resistant tumors. In addition, we observed intensive sulfatation of olomoucine II in MDCKII cell lines with subsequent active efflux of the metabolite out of the cells. Therefore, care should be taken when performing pharmacokinetic studies in MDCKII cells, especially if radiolabeled substrates are used; the generated sulfated conjugate may largely contaminate pharmacokinetic analysis and result in misleading interpretation. With regard to chemical structures of olomoucine II and purvalanol A, our data emphasize that even drugs with remarkable structure similarity may show different pharmacokinetic behavior such as interactions with ABC transporters or biotransformation enzymes.
650    _2
$a ABC transportéry $x metabolismus $7 D018528
650    _2
$a zvířata $7 D000818
650    _2
$a biologický transport $7 D001692
650    _2
$a buněčné linie $7 D002460
650    _2
$a psi $7 D004285
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a P-glykoprotein $x metabolismus $7 D020168
650    _2
$a puriny $x farmakokinetika $7 D011687
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kučera, Radim
700    1_
$a Cihalova, Daniela
700    1_
$a Klimes, Jiri
700    1_
$a Ceckova, Martina
700    1_
$a Staud, Frantisek
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 10 (2013), s. e75520
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24116053 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140704 $b ABA008
991    __
$a 20140707113741 $b ABA008
999    __
$a ok $b bmc $g 1031389 $s 862637
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 10 $d e75520 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20140704

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...